ResMedMEX:RMD 99 FCF Margin % is 35.95% as of Mar. 2026, which is 90% above its 10-year median of 18.96. GuruFocus rates MEX:RMD with a GF Score™ of 99/100 and a GF Value™ of MXN5,298.64 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, ResMed ranks better than 97.79% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. ResMed's Free Cash Flow for the
three
months ended in Mar. 2026 was MXN9,279 Mil. ResMed's Revenue for the
three
months ended in Mar. 2026 was MXN25,812 Mil. Therefore, ResMed's FCF Margin % for the quarter that ended in Mar. 2026 was 35.95%.
The historical rank and industry rank for ResMed's FCF Margin % or its related term are showing as below:
MEX:RMD'
s FCF Margin % Range Over the Past 10 Years
Min: 5.45 Med: 18.96 Max: 32.08
Current: 31.41
During the past 13 years, the highest FCF Margin % of ResMed was 32.08%. The lowest was 5.45%. And the median was 18.96%.
MEX:RMD's FCF Margin % is ranked better than 97.79% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs MEX:RMD: 31.41
ResMed FCF Margin % Related Terms
ResMed FCF Margin % Historical Data
* Premium members only.
The historical data trend for ResMed's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RMD vs MDLN, WST, BDX: FCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, ResMed's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's FCF Margin % distribution charts can be found below:
* The bar in red indicates where ResMed's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed (MEX:RMD) has a FCF Margin % of 35.95% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ResMed and its competitors. This is 90% above median its historical median of 18.96. Over the past decade, ResMed's FCF Margin % has ranged from 5.45 to 32.08. According to the industry distribution chart, ResMed ranks #18 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 2.2%.
Is ResMed's FCF Margin % too high?
ResMed's current FCF Margin % of 35.95% is 90% above median its 10-year median of 18.96. Over the past 10 years, this metric has ranged from a low of 5.45 to a high of 32.08. Based on the distribution chart, ResMed ranks #18 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ResMed has a GF Score™ of 99/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's FCF Margin % compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #18 out of 815 companies for FCF Margin %. This places ResMed in the top 2% of its industry — outperforming the majority of peers. Historically, ResMed's own FCF Margin % has ranged from 5.45 to 32.08 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on ResMed and its competitors. ResMed's current FCF Margin % is 35.95%, which is 90% above median its own 10-year median of 18.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (MEX:RMD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN5,298.64, compared to a current price of MXN3,716.10 — trading 29.9% below its estimated fair value. The current FCF Margin % is 35.95%, which is 90% above median its 10-year median of 18.96. ResMed's overall GF Score™ is 99/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For ResMed (MEX:RMD), the current FCF Margin % is 35.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (MEX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of MXN3,716.10 is trading 29.9% below its estimated GF Value™ of MXN5,298.64.
GuruFocus considers ResMed to be Significantly Undervalued.
Key valuation signals for MEX:RMD:
FCF Margin %: 35.95% (90% above median its 10-year median of 18.96)
GF Value™: MXN5,298.64 vs. price of MXN3,716.10 (29.9% below fair value)
No single metric tells the full story. See the MEX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
99GF Score
Get the complete analysis for MEX:RMD
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RMD has been successfully added to your 
